Shattuck lecture cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities

New England Journal of Medicine

Volumn 337, Issue 19, 1997, Pages 1360-1369

  Braunwald, Eugene ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Prudential Tower ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CORONARY RISK; HEART INFARCTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; MEDICAL RESEARCH; PRIORITY JOURNAL; THROMBOCYTE;

CARDIOVASCULAR DISEASES; CORONARY DISEASE; HISTORY, 20TH CENTURY; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 0030716498     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199711063371906     Document Type: Article

References (53)

1. National Center for Health Statistics. Vital statistics of the United States, 1990-1995. Vol. 2. Mortality. Part A. Washington, D.C.: Government Printing Office, 1990-1995.
2. U.S. fight on heart disease backed widely by citizens: appropriations by Congress for research equals fund for potato bug war. New York Times. July 11, 1948:3.
3. Dawber TR, Meadors GF, Moore FE Jr. Epidemiologic approaches to heart disease: the Framingham Study. Am J Public Health 1951;41:279-86.
4. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III. Factors of risk in the development of coronary heart disease - six-year follow-up experience: the Framingham Study. Ann Intern Med 1961;55:33-50.
5. Hunink MG, Goldman L, Tosteson AN, et al. The recent decline in mortality from coronary heart disease, 1980-1990: the effect of secular trends in risk factors and treatment. JAMA 1997;277:535-42.
6. Herrick JB. Clinical features of sudden obstruction of the coronary arteries. JAMA 1912;59:2015-20.
7. Antman EM, Braunwald E. Acute myocardial infarction. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. 5th ed. Philadelphia: W.B. Saunders, 1997:1184-288.
8. Kouwenhoven WB, Milnor WR, Knickerbocker GG, Chesnut WR. Closed chest defibrillation of the heart. Surgery 1957;42:550-61.
9. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction -ISIS-2. Lancet 1988;2:349-60.
10. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247:1707-14.
11. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77.
12. The Steering Committee of the Physicians' Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1988;318:262-4.
13. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396-403.
14. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106. [Erratum, BMJ 1994;308:1540.]
15. Burt V, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult U.S. population: data from the Health Examination Surveys, 1960 to 1991. Hypertension 1995;26:60-9. [Erratum, Hypertension 1996;27:1192.]
16. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.
17. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997;278:212-6.
18. Singh GK, Mathews TJ, Clarke SC, Yannicos T, Smith BL. Annual summary of births, marriages, divorces, and deaths: United States, 1994. Mon Vital Stat Rep 1995;43(13).
19. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
20. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
21. Shepherd I, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
22. Morbidity and mortality: 1996 chartbook on cardiovascular, lung and blood diseases. Bethesda, Md.: National Heart, Lung, and Blood Institute, 1996.
23. Fact book fiscal year 1996. Bethesda, Md.: National Heart, Lung, and Blood Institute, 1997.
24. 1997 Heart and stroke statistical update. Dallas: American Heart Association, 1997.
25. Hermann HC, ed. Heart watch: 1997 annual heart guide. Boston: Massachusetts Medical Society, 1997.
26. Murray CJL, Lopez AD, eds. The global burden of disease. Vol. 1 of Global burden of disease and injury series. Boston: Harvard University School of Public Health, 1996.
27. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-21.
28. Saketkhou BB, Conte FJ, Noris M, et al. Emergency department use of aspirin in patients with possible acute myocardial infarction. Ann Intern Med 1997;127:126-9.
29. Olivetti G, Giordano G, Corradi D, et al. Gender differences and aging: effects on the human heart. J Am Coll Cardiol 1995;26:1068-79.
30. Kajstura J, Cheng W, Sarangarajan R, et al. Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. Am J Physiol 1996;271:H1215-H1228.
31. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-41.
32. Bing OHL. Hypothesis: apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload. J Mol Cell Cardiol 1994;26:943-8.
33. National Center for Health Statistics, Lawrence L. Detailed diagnoses and procedures for patients discharged from short-stay hospitals: United States, 1984. Vital and health statistics: Series 13. No. 86. Washington, D.C.: Government Printing Office, 1986. (DHHS publication no. (PHS) 86-1747.)
34. Graves EJ, Gillum BS. Detailed diagnoses and procedures for patients discharged from short-stay hospitals: United States, 1994. Vital and health statistics. Series 13. No. 127. Washington, D.C.: Government Printing Office, 1997. (DHHS publication no. (PHS) 97-1788.)
35. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936-41.
36. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 1996;273:1222-5. [Erratum, Science 1997; 275:1249.]
37. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
38. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
39. Loscalzo J. Lipoprotein(a): a unique risk factor for atherothrombotic disease. Arteriosclerosis 1990;10:672-9.
40. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
41. Gurfinkel E, Bozovich G, Daroco A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. Lancet 1997;350:404-7.
42. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336:1697-703.
43. Tardif J-C, Côté G, Lespérance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997;337:365-72.
44. Gibbons GH, Dzau VJ. Molecular therapies for vascular diseases. Science 1996;272:689-93.
45. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
46. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
47. Smithies O, Maeda N. Gene targeting approaches to complex genetic diseases: atherosclerosis and essential hypertension. Proc Natl Acad Sci USA 1995;92:5266-72.
48. Breslow J. Mouse models of atherosclerosis. Science 1996;272:685-8.
49. Milano CA, Allen LF, Rockman HA, et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science 1994;264:582-6.
50. Lifton RP. Molecular genetics of human blood pressure variation. Science 1996;272:676-80.
51. Cusi D, Barlassina C, Azzani T, et al. Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997;349:1353-7
52. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
53. Isner JM, Walsh K, Symes J, et al. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation 1995;91:2687-92.